2021
Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib
Holowka T, Cheung H, Malinis M, Gan G, Deng Y, Perreault S, Isufi I, Azar MM. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. Journal Of Infection And Chemotherapy 2021, 27: 1700-1705. PMID: 34389223, DOI: 10.1016/j.jiac.2021.08.005.Peer-Reviewed Original ResearchConceptsInvasive fungal infectionsSerious infectionsRisk factorsHematologic malignanciesAdvanced ageMultivariate analysis risk factorsSmall molecule tyrosine kinase inhibitorsSingle tertiary care centerFungal infectionsConcurrent useCytotoxic agentsMolecule tyrosine kinase inhibitorsAnalysis risk factorsTertiary care centerTyrosine kinase inhibitorsElectronic medical recordsResult of infectionMost patientsClinical featuresInfected patientsMedical recordsCare centerImmune effectorsPatientsViral infection
2015
Blastomycosis in Indiana Clinical and Epidemiologic Patterns of Disease Gleaned from a Multicenter Retrospective Study
Azar MM, Assi R, Relich RF, Schmitt BH, Norris S, Wheat LJ, Hage CA. Blastomycosis in Indiana Clinical and Epidemiologic Patterns of Disease Gleaned from a Multicenter Retrospective Study. CHEST Journal 2015, 148: 1276-1284. PMID: 26020566, DOI: 10.1378/chest.15-0289.Peer-Reviewed Original ResearchConceptsDiabetes mellitusEpidemiologic patternsIncidence of blastomycosisMulticenter retrospective studyCases of blastomycosisMultilobar pneumoniaICU admissionExtrapulmonary diseaseRetrospective studyMean ageIncidence rateFungal antigensEndemic areasLarge seriesAmphotericin BBlastomycosisTotal mortalityIncidenceMellitusPneumoniaSignificant increaseDiseaseIndiana ClinicalARDSImmunosuppression